Clinical Trials Logo

Diarrhea clinical trials

View clinical trials related to Diarrhea.

Filter by:

NCT ID: NCT05509725 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Start date: August 11, 2022
Phase: Phase 4
Study type: Interventional

The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in adults with IBS-D.

NCT ID: NCT05507736 Recruiting - Solid Tumor Clinical Trials

Feasibility and Safety of Acupuncture in the Prevention of Late Irinotecan-related Diarrhea in Pediatric Patients

AIP2021
Start date: January 15, 2022
Phase: N/A
Study type: Interventional

To evaluate the feasibility of an acupuncture protocol in the prevention of late diarrhea due to irinotecan in pediatric patients with solid tumors, a pre-post pilot study will be conducted. Pre-post pilot study non-randomized, open label, single arm study. There will be a single study group that will be used at the same time as your own control. The intervention will take place for approximately one year.

NCT ID: NCT05473546 Completed - Critical Illness Clinical Trials

Diarrhea and Stipsis in Critically Ill Patients (NUTRITI)

NUTRITI
Start date: October 11, 2019
Phase:
Study type: Observational

This study prospectively observed the complications intended as diarrhea or sti-sis that critically ill patients developed within 7 days after ICU admission. In addition, secondary aims investigated through bioimpedenziometry the loss of lean body mass and changes in phase angle during the same period of ICU stay.

NCT ID: NCT05453916 Recruiting - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Start date: July 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS. We also aim to study its effect over 10 weeks after treatment to evaluate its efficacy in eradicating symptoms of IBS in the long run.

NCT ID: NCT05439772 Completed - Clinical trials for Inflammatory Bowel Diseases

Examining the Effect of Ondansetron on Bowel Prep Success

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

This is a pilot randomized-controlled trial assessing the utility of ondansetron for improving pediatric pre-colonoscopy bowel prep outcomes using the boston bowel preparation score, as well as assessing the impact on patient experience of bowel preparation.

NCT ID: NCT05430269 Recruiting - Clinical trials for Clostridium Difficile Infections

Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients

FEBATRICE
Start date: February 9, 2023
Phase: N/A
Study type: Interventional

Rationale: Postantibiotic diarrhoea in critically ill patients is common, often prolonged and currently there is no effective treatment of it. Aim: To test safety and feasibility of faecal microbial transplantation in critically ill patients with postantibiotic diarhoea. Design: Prospective, single center, parallel group randomised controlled trial. Subjects: ICU patients (both general and burn ICU) who developed diarhea after a course of antibiotic therapy that is persistent for 24 hours and is not due to other causes. Patients with septic shock or approaching death will be excluded. Treatment in the intervention group: Faecal bacteriotherapy (FBT) delivered as enema (and repeated once in the subgroup of patients with C. dif. infection) of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors. Control group: Standard-of-care protocolised treatment of postantibiotic diarhea (which includes vancomycine 250 mg p.o. 6 hourly in the subgroup with C. dif. infection). Primary outcome: Percentage of patients with treatment failure at day 7 after randomisation, which is defined as treatment either not being delivered or not being effective. Secondary and exploratory outcomes: Influence of the intervention on colonic microbiome and metabolome, small bowel and colonic permeability, bacterial translocation and systemic inflammation response to procedure.

NCT ID: NCT05405387 Recruiting - Multiple Myeloma Clinical Trials

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

IMPACT
Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

NCT ID: NCT05379036 Active, not recruiting - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome

Start date: June 23, 2021
Phase: Phase 4
Study type: Interventional

Patients with diarrhea-predominant irritable bowel syndrome (IBS) and functional dyspepsia (FD) were examined and received treatment in the study. Severity of complaints and quality of life patients were assessed according to questionnaires. The state of the intestinal barrier (analysis of the protein composition, intestinal mucin levels in biopsies, serum zonulin level in blood), the composition of the gut microbiota (16S rRNA gene sequencing), bacterial metabolic function (short-chain fatty acid levels in feces), and the presence of gut inflammation (levels of lymphocytes and eosinophils in biopsies) were assessed in the patients. Patients were divided into 3 treatment groups: trimebutin + placebo, rebamipide + placebo, trimebutin + rebamipide. The above parameters were compared in patients before and after treatment.

NCT ID: NCT05372068 Recruiting - Diarrhea Clinical Trials

Cement flooRs AnD chiLd hEalth (CRADLE)

Start date: September 24, 2023
Phase: N/A
Study type: Interventional

This randomized trial in rural Bangladesh will measure whether installing concrete floors in households with soil floors reduces child enteric infection. The trial will randomize eligible households to receive concrete household floors or to no intervention and measure effects on child soil-transmitted helminth infection, diarrhea, and other enteric infections. The study will collect longitudinal follow-up measurements at birth and when children are ages 3, 6, 12, 18, and 24 months.

NCT ID: NCT05369884 Recruiting - Clinical trials for Non-erosive Reflux Disease

Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D

Start date: December 1, 2021
Phase: Early Phase 1
Study type: Interventional

Non-erosive reflux disease(NERD)and Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)are both the common refractory gastrointestinal diseases. Patients, who suffered from overlapping symptoms of NERD and IBS-D, present more serious symptom manifestation, anxiety, and worse life quality than those with solely disease. There is lack of effective treatment for overlapping gastrointestinal symptoms. Traditional Chinese Medicine (TCM) syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence. The purpose of this study is to evaluate the efficacy and safety of WPQW granule for the treatment of NERD overlapping IBS-D.